Novartis/BeiGene Likely To Struggle In Crowded PD-1 Space Despite Positive First-Line Data
Merck’s Keytruda and BMS’s Opdivo could be tough competitors in esophageal cancer, but the Novartis/BeiGene partnership also has an anti-TIGIT drug up its sleeve.
You may also be interested in...
Novartis’s Latecomer PD-1 Outshines Keytruda And Opdivo In Esophageal Cancer
Novartis is playing catch-up in PD-1 inhibitors but could soon claim a best-in-class competitor in first-line esophageal cancer.
As Tecentriq Growth Slows, Roche’s Imminent TIGIT Readout Is Crucial
One of the year’s most important trial readouts is for Roche’s potential first-in-class TIGIT inhibitor, tiragolumab, and could help reverse a slowdown in blockbuster immunotherapy Tecentriq's growth.
Lilly To Decide Next Steps After Formal FDA 'Nay' For First Chinese PD-1
The official verdict is in for sintilimab and the results are not surprising. But some view the setback for "Made In China" innovation as a chance to reflect and move forward.